Tetraphase Pharmaceuticals, Inc.
TTPH
TTPH was delisted on the 28th of July, 2020.
90 hedge funds and large institutions have $77.5M invested in Tetraphase Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 28 increasing their positions, 27 reducing their positions, and 15 closing their positions.
33% more call options, than puts
Call options by funds: $789K | Put options by funds: $595K
10% more capital invested
Capital invested by funds: $70.7M → $77.5M (+$6.79M)
4% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 27
4% less funds holding
Funds holding: 94 → 90 (-4)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.71M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.3M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
+$657K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$604K |
| 5 |
Millennium Management
New York
|
+$594K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$3.31M |
| 2 |
BC
Broadfin Capital
New York
|
-$3.22M |
| 3 |
Renaissance Technologies
New York
|
-$1.16M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.13M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$618K |
TTPH Hedge Fund Activity: Q2 2018 in Review
90 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q2 2018, worth a combined $77.5M — up 9.6% from $70.7M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TTPH and 12 opened new positions — a net loss of 3 holders — while 27 trimmed existing stakes and 28 added.
The largest buyer was JP Morgan Chase, adding an estimated $1.71M. The largest seller was Man Group, cutting an estimated $3.31M.
- 90 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q2 2018, down from 94 in Q1 2018.
- Funds reported $77.5M of Tetraphase Pharmaceuticals, Inc. stock for Q2 2018, up 9.6% quarter-over-quarter.
- 12 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q2 2018 and 15 closed out, a net change of -3 holders.
- The largest Tetraphase Pharmaceuticals, Inc. buyer in Q2 2018 was JP Morgan Chase, an estimated $1.71M added.
- The largest Tetraphase Pharmaceuticals, Inc. seller in Q2 2018 was Man Group, an estimated $3.31M sold.
Based on aggregated 13F filings for Q2 2018.